icon
icon
icon
icon
Upgrade
Upgrade
Current data has a 15-minute delay. Please / to get real-time quotes.
icon
Key StatisticsCurrency:USD
EPS(TTM)
-1.23
P/E(TTM)
-0.94
BVPS
-1.82
P/B
-0.24
Revenue(2024 Q4)
-123.26M
YoY
-66.99%
Net Income(2024 Q4)
17.98M
YoY
131.98%
Gross Margin(TTM)
47.47%
Net Margin(TTM)
-160.63%
ROE(TTM)
--
Debt ratio
185.60%
Dividend Yield(TTM)
--
Payout Ratio
--
Unveiling the company's Dividend Strategy

Profile
Fibrogen, Inc.
A biopharmaceutical company that developing novel therapeutic agents to treat anemia, fibrotic disease, and cancer
Fibrogen, Inc., was incorporated in Delaware in 1993. FibroGen is a biopharmaceutical company dedicated to the discovery, development and commercialization of a range of best-in-class therapies. The company uses its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia inducible factor (HIF) to drive the unmet need for innovative drug treatments. Pamrevlumab is a human monoclonal antibody against CTGF for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), metastatic pancreatic cancer and Duchenne muscular dystrophy (DMD). Roxadustat (EVRENZOTM) is currently approved for the treatment of anemia in dialysis and non-dialysis CKD patients in China, Europe, Japan and many oth…More
More details
Related Sections
  • B
    Biotechnology+1.37%
Pharma Tracker
No Upcoming Event
Stay ahead with our Pharma Tracker: Monitor the latest developments in new drug research, financial health, and FDA updates for the company
More details
Revenue BreakdownCurrency:USD
Data source:2024 FY
Total
29.62M
Name
Revenue
Proportion
Development and Other
1.95M
6.58%
Drug Product
27.67M
93.42%
More details
Major shareholders
Fidelity Management & Research
The Vanguard Group
BlackRock
Astellas Pharma
Thomas B. Neff
More details
DividendsCurrency:USD

No Data

Net Income Attributable to Parent
Total Cash Dividends
Payout Ratio
Unveiling the company's Dividend Strategy

Institutional Holdings
Totally
68
institutions reported their ownerships on
FGEN
Institutional Holding Ratio
Price
Insider Transactions
Net increase
Net decrease
Price
More details
Executive Profile
More details
You Can Understand Stocks with AI.
Why NVDA surged 16.40%?
Because it
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App